[1] Shlomchik WD. Antigen presentation in graft-vs-host disease. Exp Hematol.2003;31(12):1187-1197.
[2] Csencsits KL, Bishop DK. Contrasting alloreactive CD4+ and CD8+ T cells: there’s more to it than MHC restriction. Am J Transplant.2003;3(2):107-115.
[3] Iwasaki T. Recent advances in the treatment of graft-versus-host disease. Clin Med Res.2004;2(4):243-252.
[4] Sarantopoulos S,Stevenson KE, Kim HT, et al. High levels of B-cell activating factor in patients with active chronic graft-versus-host disease.Clin Cancer Res. 2007;13(20): 6107-6106.
[5] Bacigalupo A. Management of acute graft - versus – host disease. Br J Haematol. 2007;137(2): 87-98.
[6] Keyser KA, Beagles KE, Kiem HP. Comparison of mesenchymal stem cells from different tissues to suppress T-cell activation. Cell Transplant. 2007;16(5): 555-562.
[7] Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell responses.Blood. 2005; 105(4):1815-1822.
[8] Spaggiari GM, Capobianco A, Becchetti S, et al.Mesenchymal stem cell-natural killer cell interactions:evidence that activated NK cells are capable of killing MSCs, whereas MSCs can inhibit IL-2-induced NK-cellproliferation. Blood. 2006; 107(4): 1484-1490.
[9] Corcione A, Benvenuto F, Ferretti E, et al. Human mesenchymal stem cells modulate B-cell functions.Blood. 2006;107(1): 367-372.
[10] Le Blanc K,Rasmusson I,Sundberg B,et al.Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet.2004; 363(9419): 1439-1441.
[11] Zhao K, Huang F, Peng YW, Clinical observation of mesenchymal stem cell as salvage treatment for refractory acute graft-versus-host disease. Zhonghua Xue Ye Xue Za Zhi. 2013;34(2):122-126.
[12] Introna M, Lucchini G, Dander E, et al.Treatment of Graft versus Host Disease with Mesenchymal Stromal Cells: A Phase I Study on 40 Adult and Pediatric Patients. Biol Blood Marrow Transplant. 2014 ;20(3):375-381.
[13] 张乐施,刘启发,黄科.问充质干细胞治疗糖皮质激素耐药性慢性移植物抗宿主病临床疗效观察[J].中华内科杂志,2009,48(7): 542-546.
[14] Martino R, Romero P, Subirá M,et al. Comparison of the classic Glucksberg criteria and the IBMTR Severity Index for grading acute graft-versus-host disease following HLA-identical sibling stem cell transplantation. International Bone Marrow Transplant Registry. Bone Marrow Transplant. 1999;24(3):283-287.
[15] Filipovieh AH, Weisdorf D, Pavletie S, et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-vel'Bus-Host Disease: I. Diagnosis and Staging Working Group Report. Biol Blood Marrow Transplant.2005;1l: 945-955.
[16] Gronthos S,Franklin DM,Leddy HA,et al.Surface protein characterization of human adipose tissue derived stromalcells.J Cell Physiol.2001;189(1):54-63.
[17] Campaagnoli C,Roberts IA, Kumar S, et al. Identifiction of mesenchymal stem/ progenitor cells in human first-trimester fetal blood,liver,and bone marrow. Blood.2001;98(8): 2396-2402.
[18] Igura K,ZhangX,Takahashi K,et al.Isolation and characterization of mesenchymal progenitor cells from chorionic villi of human placenta. Cytotherapy.2004; 6(6):543-553.
[19] Resnick IB, Barkats C, Shapira MY, et al.Treatment of severe steroid resistant acute GVHD with mesenchymal stromal cells (MSC). Am J Blood Res.2013;3(3):225-238.
[20] Ball LM, Bernardo ME, Roelofs H, et al.Multiple infusions of mesenchymal stromal cells induce sustained remission in children with steroid-refractory, grade III-IV acute graft-versus- host disease. Br J Haematol. 2013;163(4):501-509.
[21] Sato K, Ozaki K, Mori M, et al.Mesenchymal stromal cells for graft-versus-host disease: basic aspects and clinical outcomes.J Clin Exp Hematop. 2010;50(2):79-89.
[22] Inamoto Y,Flowers ME. Treatment of chronic graft-versus- host disease in 2011. Curr Opin Hematol.2011;18(6):414- 420.
[23] Saliba RM,de Lima M,Giralt S,et al. Hyperacute GVHD: risk factors,outcomes,and clinical implications. Blood.2007;109 (7):2751-2758.
[24] Peas PF,Fernández-Herrera J,García-Diez A. Dermatologic treatment of cutaneous graft versus host disease. Am J Clin Dermatol.2004;5 (6):403 -416.
[25] Wu PA, Cowen EW.Cutaneous graft-versus-host disease--clinical considerations and management. Curr Probl Dermatol.2012;43:101-115.
[26] Schnitzler M, Hasskarl J, Egger M,et al. Successful treatment of severe acute intestinal graft-versus-host resistant to systemic and topical steroids with alemtuzumab. Biol Blood Marrow Transplant.2009;15(8):910-918.
[27] Schub N, Günther A, Schrauder A.Therapy of steroid-refractory acute GVHD with CD52 antibody alemtuzumab is effective. Bone Marrow Transplant. 2011;46 (1):143-147.
[28] Soubani AO, Uberti JP. Bronchiolitis obliterans following haematopoietic stem cell transplantation. Eur Respir J.2007; 29(5): 1007-1019.
[29] Bergeron A, Godet C, Chevret S,et al.Bronchiolitis obliterans syndrome after allogeneic hematopoietic SCT: phenotypes and prognosis. Bone Marrow Transplant. 2013;48(6): 819-824.
[30] Fraile P, Vazquez L, Caballero D, et al.Chronic graft-versus-host disease of the kidney in patients with allogenic hematopoietic stem cell transplant. Eur J Haematol. 2013;91(2):129-134
[31] Cutis RE,Travis LB,Rowlings PA,et al. Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study. Blood.1999;94(7):2208-2216.
[32] Seçkin D, Barete S, Euvrard S, et al.Primary cutaneous posttransplant lymphoproliferative disorders in solid organ transplant recipients: a multicenter European case series. Am J Transplant. 2013;13(8):2146-2153.
[33] Weinstock DM,Ambrossi GC,Brennan C, et al.preempitive diagnosis and treatment of Epstein-Barr virus-associated posttransplant lymphoproliferative disorder after hematopoietic stem cell transplant: an approach in development.Bone Marrow Transplant. 2006;37(6):539-546.
[34] Liu XD, Fan ZP, Peng YW, et al. The outcome and safety of mesenchymal stem cells from bone marrow of a third party donor in treatment of secondary poor graft function following allogeneic hematopoietic stem cell transplantation.Zhonghua Xue Ye Xue Za Zhi.2012;33(2):98-102. |